NCT04669028 - A Phase 3 Study of NE3107 in Probable Alzheimer's Disease | Biotech Hunter

Enrollment

439

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

September 30, 2023

Study Completion Date

October 25, 2023

Conditions

Alzheimer Disease

Interventions

DRUG

NE3107

NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.

DRUG

Placebo

capsules that do not contain NE3107

Trial Locations (1)

43221

The Ohio State University, Columbus